Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Important readouts for ianalumab, Cosentyx® and ligelizumab Selected data readouts 3 INNOVATION lanalumab Ph2b Sjögren's Syndrome ■ High unmet need, 400k patients¹, no DMT Primary efficacy endpoint met; dose response defined as change in ESSDAI from baseline at 24 weeks² ESSDAI score change over time Least-squares mean change in ESSDAI score from baseline -6- -8 -10 0 ■ Good tolerability Placebo lanalumab 5 mg lanalumab 50 mg lanalumab 300 mg 8 16 20 24 Time from baseline (weeks) CosentyxⓇ Ph3 HS (SUNRISE/SUNSHINE) ◉ High unmet need in HS3 Primary efficacy endpoint of HiSCR at week 16 met in both studies ■ HiSCR response: ≥50% decrease4 ■ Favorable safety profile confirmed Next steps ■ Studies remain blinded, data will be presented after week 52 Proceeding to 1st submission Q2 ☐ Ligelizumab Ph3 CSU (PEARL1&2) ◉ Superiority demonstrated vs. placebo but not vs. omalizumab Next steps ■ Ph3 start H2 2022 Other indications: Lupus Nephritis (Ph3 to be initiated 2022), SLE and AIH (Ph2), B-cell malignancies (Ph1/2) Next steps ■ Evaluation of Ph3 data continuing ■ Data release on completion H2 2022 ☐ CINDU, food allergy studies continue HiSCR: Hidradenitis Suppurativa Clinical response 1. with moderate to severe SjS disease in G7. 2. Bowman et al, The Lancet 2021, in press. 3. Available treatments do not adequately reduce disease activity or prevent disease progression; -400k patients with moderate to severe HS: 200k patients US, 200k patients EU5; source: British Journal of Derm. 4. in Abscess and Inflammatory Nodule count with no increase in the no. of draining fistulae. 14 Investor Relations | Q4 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation